Skip to content
ESE logo
Mineralocorticoid antagonists may be a novel treatment for alcohol use disorder

According to the National Institute on Alcohol Abuse and Alcoholism (NIAAA)Trusted Source, a division of the National Institutes of Health (NIH), alcohol use disorder “is a medical condition characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences.”

Normally used to treat cardiovascular disease, the mineralocorticoid antagonist spironolactone has now shown efficacy in decreasing alcohol intake. The study investigated the effects on alcohol consumption in mice, rats and people and is published in Molecular Psychiatry.

Read more on Medical News Today